Accession Number:

AD1045667

Title:

68Ga Bombesin PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Noncontributory Conventional Imaging

Descriptive Note:

Technical Report,30 Sep 2016,29 Sep 2017

Corporate Author:

The Leland Stanford Junior University Stanford United States

Personal Author(s):

Report Date:

2017-10-01

Pagination or Media Count:

9.0

Abstract:

Purpose 68Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 68Ga-RM2 is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptors GRPr. GRPr proteins are highly overexpressed in several human tumors, including prostate cancer PCa.Methods We enrolled 15 men with biochemically recurrent PCa from May to Sep 2017, 63-79 year-old mean standard deviationSD 70.34.3. Imaging started at 41-89 minutes mean SD 53.614.1 after injection of 127.5-146.5 MBq mean SD 141.04.7of 68Ga-RM2 using a time-of-flight TOF-enabled simultaneous positron emission tomography PET magnetic resonance imagingMRI scanner. T1-weighted T1w, T2-weighted T2w and diffusion-weighted images DWI were acquired. Results All patients had rising prostate specific antigen PSA range 0.2-12.5 ngmL mean SD 4.24.4 and negative CI CT or MRI, and 99mTc MDP bone scan prior to enrollment. The observed 68Ga-RM2 PET detection rate was 73.3 . 68Ga-RM2 PET identified recurrent PCa in 11 of the 15 participants.Conclusions 68Ga-RM2 PET can be used for assessment of GRPr expression in patients with biochemically recurrent PCa. High uptake in multiple areas compatible with cancer lesions suggests that 68Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in participants with biochemically recurrent PCa and negative conventional imaging.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE